How to Position Your Money for Big Profits Before the Next Big M&A Announcement

Please do not reply to this message. Replies to this message are routed to an unmonitored mailbox. You are receiving this email as a part of your subscription to Total Wealth. Your ability to alter your subscription information can be found at the bottom of this email. [Total Wealth] January 24, 2018 [What Does a Traffic Light Have to Do With Your Next Huge Payday?]( Imagine if I told you the secret to scoring huge gains from the market could be as simple as "green light," go, "red light," stop? This simple pattern shows up in dozens of stocks, every single day... and by using it as part of my strategy, I've shown my readers the chance at average WEEKLY gains that could turn a small amount into $15,690 in extra cash a week. [It's easier than you think](... --------------------------------------------------------------- Keith Fitz-Gerald's PREMIUM SERVICES Research [This Company Has Already Doubled the S&P's Performance - and We Own It]( Current Open Positions: 65 Avg. 2017 Returns: 55.51% Trading [Six Recommendations and a Profit to End Your Trading Day]( Current Open Positions: 52 Avg. 2017 Returns: 45.32% Director of Research, Sid Riggs, gave members an opportunity at over 20 triple-digit winners in 2017, all from stocks trading under $48/share... and 2018 is shaping up to be even better than that. [Click here]( to gain access. IN THE MEDIA [How Thousands of Americans Will Prosper this Year Watch the full video here.]([How to Position Your Money for Big Profits Before the Next Big M&A Announcement]( Dear Total Wealth Investor, When I started Total Wealth I promised you three things: a) I'd do my best to help you identify where the world's big money is moving, b) how to identify which companies are best positioned to profit and c) what specific steps you can take to "get your money there first." Today I'm going to keep that promise by showing you a simple yet potentially very profitable way to identify the next merger and acquisition candidate in any industry before it's announced. Obviously, no method is foolproof but all you have to be is "close enough" in this business when money's on the move. It's Tuesday morning as I write and I'm looking at headlines related to two of the biggest pharma mergers announced this year. Frankly, I'm drooling in light of what I've just told you... at least mentally anyway. Let me tell you why. News broke Monday that Celgene Corp. ([NasdaqGS:CELG]() is buying Juno Therapeutics Inc. ([NasdaqGS:JUNO]() for $9 billion and Sanofi ([NYSE:SNY]() is buying Bioverativ Inc. ([NasdaqGS:BIVV]() for $11.6 billion. Between the two companies, that's a staggering $20.6 billion on the move in a sector projected to hit $1.2 trillion - with a "T" - by 2022. But, as great as that sounds, it's not why I'm writing today. Anybody who's trying to profit from what was just announced has already missed the train. They're going to have to play catch-up. My goal is to show you how to identify and profit from what happens next by getting your money there first and ahead of the next major news blast. --------------------------------------------------------------- [You wanted something better from us (well, here it is)]( We've gotten your letters... We've heard your complaints, loud and clear. You want something BIGGER from us... Something that could make you SUPERIOR returns... in just DAYS... A service that is better and bolder than any initiative we've undertaken so far... Well, here it is... [Watch this]( and you'll thank me later. --------------------------------------------------------------- Here's the thing... What most investors fail to realize is that deals like the two I've just mentioned have implications far beyond current headlines. Which means, in turn, that there's huge profit potential waiting in the wings if you know what to look for. Mergers and acquisitions, you see, rarely happen in isolation. Instead, they produce clusters of activity as other industry players jockey for position and are forced to make acquisitions of their own to "keep up." For example, U.S. Airways touched off a string of mergers in the airline industry back in 2005 that consolidated nine of the largest airline companies into just four... for the simple reason that fleet size, routing, and the number of landing slots determines who's king of the proverbial mountain - or the runway as the case may be. It's the same thing in the energy business. Starting in 2015, there have been a string of mergers with stronger players gobbling up weaker players in a bid to consolidate their leadership and profitability. Examples include Royal Dutch Shell plc ([NYSE:RDS.A]() buying out BG Group, and Enbridge Inc. ([NYSE:ENB]() acquiring Spectra Energy - which were together worth a staggering $98 billion. Today it's pharma where new pipelines, new drugs, and new products are critical to future cash flow. Celgene is buying Juno to compete in the oncology space against Novartis AG ([NYSE:NVS]() and Gilead Sciences Inc. ([NasdaqGS:GILD](). Sanofi is buying Bioverativ to compete against Bayer AG ([OTC:BAYRY]() and Nova Nordisk A/S ([NYSE:NVO]() in the hemophilia space. Other deals will follow, and that's what makes situations like this one so appealing - you will not run out of opportunities any time soon. Long-established companies, like Celgene and Sanofi, are under tremendous pressure to replace aging treatments on a downward revenue trajectory with high-value replacement therapies worth billions of dollars. That means they have to keep buying - like a rat on a treadmill has to keep running. --------------------------------------------------------------- [Forget Bitcoin (This is the greatest tech breakthrough of the century)]( A tiny Silicon Valley company just sent shockwaves throughout the tech world. The FCC recently approved [a revolutionary new device]( capable of something amazing... something most people thought was impossible. The Washington Times says the technology behind the device, "will change the world on a scale hardly seen in human history." [You need to see this to believe it](... --------------------------------------------------------------- To a savvy investor or trader, this is a lot like going fishing and knowing exactly where the fish are biting. Or, playing poker and knowing which players at the table have to make a move. It's information that dramatically boosts your odds of success - not to mention your profit potential, too. Most investors, of course, will never make the connection. That's bad for them but great for you because it means you've got a tightly defined window of opportunity to buy shares before the herd arrives and jacks the price up. Here's a simple 3-step trade setup you can use to play the situation. While there's a lot to like, I am particularly partial to the fact that the method I'm going to share with you is easy to understand and even easier to implement. What's more, you can use it in any industry where mergers and acquisition headlines heat up. [CRITICAL] [520% in Average Gains Each Week Could be as Easy as Spotting an 'X']( Step 1: Find your headlines Most investors read the headlines and the information in 'em goes in one ear and out the other. They don't "hear" what the news is trying to tell them - which is too bad because discovering huge profits is all about recognizing opportunity. In this case, we're talking about two of the biggest players acting in near unison, so I need to re-emphasize: Celgene Corp. ([NasdaqGS:CELG]() is buying Juno Therapeutics Inc. ([NasdaqGS:JUNO]() for $9 billion and Sanofi ([NYSE:SNY]() is buying Bioverativ Inc. ([NasdaqGS:BIVV]() for $11.6 billion. There are several key bits of information here. First, you know exactly what sector is hot. Second, you know who's making their play. And, third, you know who's got to catch up. In that sense, the headlines are a dead giveaway to where the hot money is headed next. Step 2: Find high probability targets Most investors would give anything to have an inside track when it comes to identifying likely merger and acquisition candidates for the simple reason that putting your money ahead of the next big announcement can be extraordinarily profitable. For example, savvy investors who had their money in Bioverativ on January 19th are now looking at a quick, easy 64% pop because Sanofi's offer stands at $105 a share. That's enough to turn every $10,000 into at least $16,400 just because they had their money in the right place at the right time. The easiest way to get in on the action ahead of time is to run a simple screen using your favorite online financial portal. It doesn't really matter whether you're partial to Google Finance, Yahoo! Finance, MSN Money, or any of a dozen other sites. What you're looking for is the ability to put in a ticker and have a list of related companies pop up when you do. Cross reference the results using a few different search engines and - voila - you've got a short list of buyout candidates. The entire process takes about 10 minutes. From there it's simply a matter of a little homework and a few educated guesses. --------------------------------------------------------------- [Feeding Frenzy!]( At this moment, a tiny $2 million company is on the leading-edge of a whole new energy sub-niche. In fact, they've harnessed a mind-blowing technology that unlocks America's new $7 trillion energy bounty. And now, the Department of Energy has delivered a shocking proposal that could send this company soaring to a 59,580% revenue-surge. Insiders are swarming. The Chairman just slapped down a $346 million personal wager. And Citibank just accelerated its holding by 2,622%. The time is now to seize your shot at history. [HURRY](! --------------------------------------------------------------- On that note, let's focus on Celgene. The company is clearly on the hunt, and my guess is that the Celgene will look very closely at previously established partners with late stage clinical trials underway that could easily be turned into blockbuster drugs producing billions in revenue. Executives don't like complicated setups, either. I've got to imagine that Bluebird Bio Inc. ([NasdaqGS:BLUE]() is a primary target. The company's name popped up on five of the six internet searches I used on various financial sites as a related company or something "People Also Watch" on Yahoo! Finance, for example. That makes complete sense. Bluebird's apparently been working with Celgene since 2013 and has several late stage clinical trials and candidates in progress for high value drugs aimed at treating transfusion dependent beta-thalassemia and cerebral adrenoleukodystrophy. That means it's a known quantity. What's more, I can easily envision a bidding war developing later this year because those same areas are also product lines that would be of extraordinary interest to competitors like Amgen Inc. ([NasdaqGS:AMGN](), Johnson & Johnson ([NYSE:JNJ](), and Gilead Sciences Inc. ([NasdaqGS:GILD](). That means there's likely to be plenty of interest and some terrific profit potential for any investor who gets his or her money "there" ahead of time. [VIDEO] [Now GE's Got Another Problem (and It Could Clobber Unsuspecting Investors)]( Step 3: Line up your trade The simplest way to play a situation like this is to buy stock in the company or companies you identify as targets - in this case, Bluebird Bio Inc. ([NasdaqGS:BLUE](). Or, if you're interested in something spicier and more aggressive, consider buying call options on Bluebird stock with an expiration date at least a year away; that way you're in for a fraction of the capital but still maintain the time horizon needed for a deal like this one to play out, assuming we're correct. My suggestion is the Jan 17 2020 $195 Call Options ([BLUE200117C00195000](). As always, though, you don't want to bet the farm. Buying pre-acquisition candidates is a speculative trade. As such, that means it's something you want to do in conjunction with your established investments, not in lieu of them. The simplest way to control risk is to [limit the amount of capital to 2%](. That way you're still on track for ginormous profits but won't blow up your portfolio if the markets have other ideas. I'll be with you every step of the way. Until next time, Keith Fitz-Gerald Chief Investment Strategist --------------------------------------------------------------- More from Keith... [The Most Important Lesson I've Ever Learned is Also the Most Valuable]( Apple Inc. ([NasdaqGS:AAPL]() rocked markets this past Wednesday, when the company announced that it's going to make a $350 billion contribution to the U.S. economy over the next five years, hire at least 20,000 new employees, open a new campus, and more. The question, of course, becomes "what's next?" [[Full Story](] Pop Quiz! How Will Cryptocurrency Funds Make it Past the SEC? While millions of investors are pumped to start playing cryptocurrency, the SEC just threw two Wall Street trade groups for a loop. If you are a long-time reader, you'll know that this is Shah Gilani's Bat-Signal; breaking down gated information for anyone to be able to digest is his favorite pastime. To read Shah's study guide to the SEC's crypto pop quiz - and to sign up for his free, twice-weekly Wall Street Insights & Indictments - [click here](. [How to Trade the Next Crypto-Craze Crash]( Bitcoin went into freefall before coming to a rest at $9,199.59 early Wednesday morning, some 52% below its all-time high as a worldwide digital selloff intensified - roughly 19% of which happened in less than 24 hours. To put this in perspective, you're talking about a $30 billion buzzcut that would have wiped GoPro Inc. ([NasdaqGS:GPRO](), Fitbit Inc. ([NYSE:FIT](), and Twitter Inc. ([NYSE:TWTR](), combined, from the face of the earth. [[Here's what you need to do](] --------------------------------------------------------------- You Also May Have Missed... - [Here's what you should know about California's marijuana legalization]( - [The Fate of America Lies in the Hands of This Tiny Defense Contractor]( - [You Could Have Made $68,870 by "Enrolling" in Just One of These Programs]( - [Your $1 million payday opportunity awaits]( --------------------------------------------------------------- Share [Facebook]( [Twitter]( [More...]( mailto:?subject=Keith%20Fitz-Gerald's%20Total%20Wealth%20Research&body=Check%20out%20http%3A%2F%2Fwww.totalwealthresearch.com%2F --------------------------------------------------------------- You are receiving this e-mail at, {EMAIL}, as a part of your free subscription to Total Wealth. Remove your email from this list: [Unsubscribe]( To cancel by mail or for any other subscription issues, write us at: Total Wealth | Attn: Member Services | 1125 N Charles Street | Baltimore, MD 21201 North America: 888.384.8339; International: 443.353.4519; Fax: 410.622.3050 [Contact Customer Service]( Website: []( © 2018 Total Wealth All Rights Reserved. Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized financial advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. This Newsletter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of: Total Wealth Research. 1125 N Charles Street, Baltimore MD 21201.